1.Liver transplantation for hepatic metastatic pancreatic insulinoma with a survival over five years.
Xiao-Bo CHEN ; Jie YANG ; Ming-Qing XU ; Lü-Nan YAN
Chinese Medical Journal 2012;125(15):2768-2771
Pancreatic neuroendocrine tumors (NETs) are one subgroup of gastroenteropancreatic NETs. Its main characteristics are slow growth, frequent metastasis to the liver, and limited to the liver for long periods. In patients with irresectable liver metastatic NET, liver transplantation is the only radical treatment. About 160 cases of liver transplantation for liver metastatic NET have been reported worldwide. However, there is no such report of liver transplantation for hepatic metastatic NET in China by now. We herein report a case of liver transplantation for hepatic metastatic pancreatic insulinoma with a survival of over 5 years.
Humans
;
Insulinoma
;
secondary
;
therapy
;
Liver Neoplasms
;
complications
;
Liver Transplantation
;
Male
;
Middle Aged
;
Pancreatic Neoplasms
;
secondary
;
therapy
2.Pancreatitis from Metastatic Small Cell Lung Cancer: Successful Treatment with Endoscopic Intrapancreatic Stenting.
Jong Shin WOO ; Kwang Ro JOO ; Yong Sik WOO ; Jae Young JANG ; Young Woon CHANG ; Joung Il LEE ; Rin CHANG
The Korean Journal of Internal Medicine 2006;21(4):256-261
Lung cancer metastases can occur in almost any organ. However, metastasis of small cell lung cancer to the pancreas is rare. Moreover, not all cases present with clinically diagnosed pancreatitis. We recently treated a patient with small cell lung carcinoma that invaded the pancreatic duct causing acute pancreatitis. Generally, the treatment for tumor-induced acute pancreatitis is initially supportive followed by aggressive chemotherapy or surgery. If the patient can tolerate the insertion of an endoscopic intrapancreatic stent, this is performed in addition to chemotherapy and surgery; this approach offers a safe and effective treatment modality for such patients.
Tomography, X-Ray Computed
;
*Stents
;
Prosthesis Implantation/*methods
;
Pneumonectomy
;
Pancreatitis/diagnosis/etiology/*surgery
;
Pancreatic Neoplasms/*complications/secondary/therapy
;
Pancreatic Ducts/radiography/*surgery/ultrasonography
;
Middle Aged
;
Lung Neoplasms/*pathology/therapy
;
Humans
;
Follow-Up Studies
;
Female
;
Endosonography
;
Cholangiopancreatography, Endoscopic Retrograde
;
Carcinoma, Small Cell/*complications/secondary/therapy
;
Antineoplastic Agents/therapeutic use
3.En bloc Resection for Right Colon Cancer Directly Invading Duodenum or Pancreatic Head.
Won Suk LEE ; Woo Yong LEE ; Ho Kyung CHUN ; Seong Ho CHOI
Yonsei Medical Journal 2009;50(6):803-806
PURPOSE: We undertook this study to analyze clinical features and surgical outcome of en bloc resections of the right side colon cancer directly invading duodenum and/or pancreatic head. MATERIALS AND METHODS: The records of all patients who underwent en bloc resection of duodenum and/or pancreas for right colon cancers were analyzed retrospectively. From September 1994 to September 2006, 1,016 patients underwent curative right hemicolectomy. Nine patients (0.9%) had en bloc resection of a right side colon cancer with duodenum or pancreatic head invasion. RESULTS: The median operative time was 320 minutes (range, 200-420) and the median blood loss was 700 mL (range, 100-2,000). The mean size of tumor was 6.6 cm (range, 3.2-10.7). The mean preoperative carcinoembryonic antigen (CEA) was 10.6 ng/mL (range, 0.2-50.8). There was no 30 day perioperative mortality. The median disease-free survival was 23.5 months [95% confidence interval (CI) 5.2-41.8] and the median overall survival was 28.1 months (95% CI 9.7-46.5). CONCLUSIONS: In patients with locally advanced right side colon cancer that directly invades the duodenum or pancreas can be safely resected with curative potential with minimum morbidity and mortality. Long term disease free survival can occur in a significant number of patients undergoing curative en bloc resection in this particular subset of patients.
Adult
;
Aged
;
Camptothecin/analogs & derivatives/pharmacology/therapeutic use
;
Chemotherapy, Adjuvant
;
Colonic Neoplasms/*complications/drug therapy/mortality/*surgery
;
Disease-Free Survival
;
Duodenal Neoplasms/drug therapy/mortality/*secondary/surgery
;
Duodenum/drug effects/*pathology/surgery
;
Female
;
Fluorouracil/pharmacology/therapeutic use
;
Humans
;
Leucovorin/pharmacology/therapeutic use
;
Male
;
Middle Aged
;
Organoplatinum Compounds/pharmacology/therapeutic use
;
Pancreas/drug effects/*pathology/surgery
;
Pancreatic Neoplasms/drug therapy/mortality/*secondary/surgery
;
Retrospective Studies
;
Treatment Outcome